Evidence map›Paper›PMID 39533806›Full record

ArticleCancer medicine2024

Prevalence and Significance of AGR2 Expression in Human Cancer.

Nina Schraps, Jacob Constantin Port, Anne Menz, Florian Viehweger, Seyma Büyücek, David Dum, Ria Schlichter, Andrea Hinsch, Christoph Fraune, Christian Bernreuther and 22 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Nina SchrapsGeneral, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID https://orcid.org/0009-0001-3056-2974
Jacob Constantin PortInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Anne MenzInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Florian ViehwegerInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Seyma BüyücekInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID https://orcid.org/0000-0002-9106-6595
David DumInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ria SchlichterInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Andrea HinschInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Christoph FrauneInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Christian BernreutherInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Martina KluthInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Claudia Hube-MaggInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Katharina MöllerInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Viktor ReiswichInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Andreas M LuebkeInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Patrick LebokInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Sören WeidemannInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Guido SauterInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Maximilian LennartzInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Frank JacobsenInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Till S ClauditzInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Andreas H MarxInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ronald SimonInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID https://orcid.org/0000-0003-0158-4258
Stefan SteurerGeneral, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Baris MercanogluInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Nathaniel MellingInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Thilo HackertInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Eike BurandtGeneral, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Natalia GorbokonGeneral, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Sarah MinnerGeneral, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Till KrechGeneral, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Florian LutzGeneral, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backroundAnterior gradient 2 (AGR2) is a resident endoplasmic reticulum (ER) protein with a vital role in embryonal development, mucus maturation, tissue regeneration, and wound healing.

methodsTo determine the prevalence and clinical significance of AGR2 expression in cancer, a tissue microarray containing 14,966 tumors from 134 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry (IHC).

resultsAGR2 positivity was found in 103 of 134 tumor categories, and 83 tumor categories contained at least one strongly positive case. AGR2 expression was most frequently seen in tumors of the female genital tract, particularly adenocarcinomas (up to 100%), various breast cancer subtypes (57.1%-100%), urothelial carcinoma (74.6%-100%), adenocarcinomas of the upper and lower gastrointestinal tract (93.6%-99.6%), and pancreaticobiliary cancers (65.2%-98.2%). AGR2 positivity was slightly less common in squamous cell carcinomas (46.4%-77.3%) and mainly absent in mesenchymal and lymphoid tumors. While AGR2 expression was only weak or absent in the normal thyroid, it was moderate to strong in 46.0% of adenomas, 52.8% of follicular carcinomas, and 81.8% of papillary carcinomas of the thyroid. High AGR2 expression was strongly linked to poor ISUP (p < 0.0001), Fuhrman (p < 0.0001), and Thoenes (p < 0.0001) grades as well as advanced pT stage (p = 0.0035) in clear cell renal cell carcinoma (ccRCC). Low AGR2 expression was associated with high BRE grade in breast cancer (p = 0.0049), nodal metastasis (p = 0.0275) and RAS mutation (p = 0.0136) in colorectal cancer, nodal metastasis (p = 0.0482) in endometrioid endometrial carcinoma, high grade in noninvasive urothelial carcinoma (p = 0.0003), and invasive tumor growth in urothelial carcinoma (p < 0.0001).

conclusionsIt is concluded that AGR2 expression occurs in a broad range of different tumor entities and that AGR2 assessment may serve as a diagnostic aid for the distinction of thyroidal neoplasms and as a prognostic marker in various cancer types.

Indexed as

Biomarkers, TumorMucoproteinsNeoplasmsOncogene ProteinsFemaleHumansImmunohistochemistryMalePrevalencePrognosisProteinsTissue Array AnalysisAGR2 protein, humanBiomarkers, TumorMucoproteinsOncogene ProteinsProteins

Identifiers

PMID39533806
PMCPMC11557986

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.